HPV vaccination: principles, results and future perspectives;Vaccination HPV : principes, résultats et perspectives

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 36, Issue 1, 2007, Pages 13-18

  Rouzier, R ^a,b   Uzan, C ^b   Collinet, P ^c  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b HÔPITAL TENON   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical trial; Human papillomavirus; Target; Vaccine

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MORBIDITY; MORTALITY; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 34247248192     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2006.10.006     Document Type: Review

References (37)

1. Hill C., and Doyon F. Frequency of cancer in France: 2004 update. Bull. Cancer 91 (2004) 9-14
2. Reagan J.W., and Wentz W.B. Genesis of carcinoma of the uterine cervix. Clin. Obstet. Gynecol. 10 (1967) 883-921
3. Kottmeier H.L. The development and treatment of epitheliomas. Rev. Fr. Gynecol. Obstet. 56 (1961) 821-826
4. Rotkin I.D. A comparison review of key epidemiological studies in cervical cancer related to current searches for transmissible agents. Cancer Res. 33 (1973) 1353-1367
5. Orth G., and Croissant O. Human papillomavirus and carcinogenesis of the uterine cervix: future prospects in the domain of detection and prevention. Bull. Acad. Natl. Med. 181 (1997) 1365-1392 (discussion 1392-1364)
6. Collins S., Mazloomzadeh S., Winter H., Blomfield P., Bailey A., Young L.S., et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109 (2002) 96-98
7. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis. 191 (2005) 1808-1816
8. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181 (2000) 1911-1919
9. Riethmuller D., Gay C., Bertrand X., Bettinger D., Schaal J.P., Carbillet J.P., et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn. Mol. Pathol. 8 (1999) 157-164
10. Stoler M.H. HPV for cervical cancer screening: is the era of the molecular pap smear upon us?. J. Histochem. Cytochem. 49 (2001) 1197-1198
11. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 (2005) 1072-1079
12. Wentzensen N., Vinokurova S., and von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64 (2004) 3878-3884
13. Rock C.L., Michael C.W., Reynolds R.K., and Ruffin M.T. Prevention of cervix cancer. Crit. Rev. Oncol. Hematol. 33 (2000) 169-185
14. Duarte-Franco E., and Franco E.L. Cancer of the uterine cervix. BMC Womens Health 4 Suppl 1 (2004) S13
15. Schaffer P., Sancho-Garnier H., Fender M., Dellenbach P., Carbillet J.P., Monnet E., et al. Cervical cancer screening in France. Eur. J. Cancer 36 (2000) 2215-2220
16. McIndoe W.A., McLean M.R., Jones R.W., and Mullins P.R. The invasive potential of carcinoma in situ of the cervix. Obstet. Gynecol. 64 (1984) 451-458
17. Fédération des Gynécologues et Obstétriciens de langue française. Conférence de consensus sur le dépistage du cancer du col. J. Gynecol. Obstet. Biol. Reprod. 5bis (1990) 7-16
18. Agence Nationale d'Accréditation et d'Évaluation en Santé. Conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal. Actualisation 2002 (2002)
19. Rousseau A., Bohet P., Merlière J., Treppoz H., Heules-Bernin B., and Ancelle-Park R. Évaluation du dépistage organisé et du dépistage individuel du cancer du col de l'utérus : utilité des données de l'assurance maladie. BEH 19 (2002) 81-83
20. Mubiayi N., Bogaert E., Boman F., Leblanc E., Vinatier D., Leroy J.L., et al. Histoire du suivi cytologique de 148 femmes atteintes d'un cancer invasif du col utérin. Gynecol. Obstet. Fertil. 30 (2002) 210-217
21. Insinga R.P., Glass A.G., and Rush B.B. The health care costs of cervical human papillomavirus: related disease. Am. J. Obstet. Gynecol. 191 (2004) 114-120
22. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
23. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67 (1993) 6929-6936
24. Hagensee M.E., Yaegashi N., and Galloway D.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67 (1993) 315-322
25. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
26. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
27. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
28. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intra-epithelial neoplasia: a randomised controlled trial. Obstet. Gynecol. 107 (2006) 18-27
29. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
30. Villa L.L., Costa R.L., and Petta C.A. Efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle through up to 5 years follow-up. Eurogin (2006) (Paris). http://www.eurogin.com/2006/docs/EUROGIN2006-Addendum.pdf
31. http://www.emea.eu.int/humandocs/Humans/EPAR/gardasil/gardasil.htm.
32. Brun J.L. Résultats de l'essai de phase II du vaccin thérapeutique anti-HPV pour le traitement des lésions précancéreuses du col de l'utérus. Eurogin (2006) (Paris). http://www.eurogin.com/2006/docs/EUROGIN2006-Abstracts.pdf (p. 233)
33. Olsson S.E., and for the FUTRE II study group. Post-infection prophylaxis quadrivalent HPV (types 6/11/16/18) L1 virus-like particle vaccine. A combined analysis. Eurogin (2006) (Paris). http://www.eurogin.com/2006/docs/EUROGIN2006-Abstracts.pdf (p. 240)
34. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. 96 (2004) 604-615
35. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10 (2004) 1915-1923
36. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis. 9 (2003) 37-48
37. Ekalaksananan T., Pientong C., Sriamporn S., Kongyingyoes B., Pengsa P., Kleebkaow P., et al. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. Gynecol. Oncol. 103 (2006) 62-66